Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$28.3MCash on Hand
84.6mo Cash Runway
Follow SXTC by emailGet an email when SXTC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SXTC, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 21, 2026 ·
Financing China SXT Pharmaceuticals terminated the over-allotment option that would have let investors buy up to $12,000,000 of additional securities in its October 2026 registered direct offering. The termination does not affect securities already issued in the offering. Form 6-K · SEC filing · Press release
Oct 9, 2026 ·
Financing China SXT Pharmaceuticals is offering up to 8,000,000 units at $1.50 per unit, for up to $9,000,000, with Univest Securities as placement agent on a best-efforts basis. Each unit includes a warrant exercisable at $2.75, with a zero-price exercise feature, and an over-allotment option of up to $12,000,000. Form 424B5 · SEC filing
Oct 9, 2026 ·
Financing Announced a registered direct offering of 8,000,000 units at $1.50 per unit, with expected gross proceeds of about $12,000,000 before placement agent fees and expenses. Each unit includes a share or pre-funded warrant plus a warrant exercisable at $2.75 for one year. Form 6-K · SEC filing
Oct 8, 2026 ·
Financing China SXT entered a Securities Purchase Agreement on October 7, 2026 for a private placement of 3,000,000 Class A ordinary shares and warrants for 3,000,000 shares at $1.00 per share, for gross proceeds of $3 million. Form 6-K · SEC filing
Oct 8, 2026 ·
Financing Corrects a typo in the October 8 press release: the warrants' initial exercise price is $2.75 per Class A ordinary share, not the figure originally printed. The revised release is attached as Exhibit 99.1. Form 6-K · SEC filing · Press release
Aug 28, 2026 ·
Financing Amended the July 3, 2026 securities purchase agreement with an institutional investor, lowering the floor price for pre-paid purchases of Class A ordinary shares from $16.00 to $0.20 per share, after a 1-for-80 share consolidation on August 10, 2026 had raised it from $0.20. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SXTC holds $28.3M in cash and short-term investments and burns about $1M/quarter from operations,
an estimated runway of 84.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:40 · Elevated
Cash runway 85 months
ATM program on file since Jun 2026 +15
Shelf registration (F-3, Jul 2026) +10
Going-concern doubt in the latest 20-F +15These factors raise substantial doubt about the Company’s ability to continue as a going concern.20-F, Jul 2026
Share count 958,077 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SXTC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SXTC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.